Biotinidase deficiency (BD) is an autosomal recessive disorder resulting in the inability to recycle the
vitamin biotin. Individuals with
biotinidase deficiency can develop neurological and cutaneous symptoms if they are not treated with
biotin. To date, more than 165 mutations in the
biotinidase gene (BTD) have been reported. Essentially all the mutations result in enzymatic activities with less than 10% of mean normal serum
enzyme activity (profound
biotinidase deficiency) with the exception of the c.1330G>C (p.D444H) mutation, which results in an
enzyme having 50% of mean normal serum activity and causes partial
biotinidase deficiency (10-30% of mean normal serum
biotinidase activity) if there is a mutation for profound
biotinidase deficiency on the second allele. We now reported eight novel mutations in ten children identified by newborn screening in Michigan from 1988 to the end of 2012. Interestingly, one intronic mutation, c.310-15delT, results in an approximately two-fold down-regulation of BTD
mRNA expression by Quantitative real-time reverse-transcription PCR (qRT-PCR). This is the first report of an intronic mutation in the BTD gene with demonstration of its effect on enzymatic activity by altering
mRNA expression. This study identified three other mutations likely to cause partial
biotinidase deficiency. These results emphasize the importance of full gene sequencing of BTD on patients with
biotinidase deficiency to better understand the genotype and phenotype correlation in the future.